NEW YORK (GenomeWeb) – Abbott today reported that its diagnostics sales jumped 5 percent year over year in the second quarter, but molecular diagnostics was a drag on the business, falling 2 percent.

The medical products giant reported total revenues of $5.55 billion for the quarter ended June 30, up 2 percent from $5.45 billion for Q2 2013.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.